IP Library Granted Patent US 11,738,199
Granted Patent B2
US 11,738,199 · App. 17/390,481 · Granted Aug 29, 2023

Neurostimulation in a neural fulcrum zone for the treatment of chronic cardiac dysfunction

Inventors: Bruce H. KenKnight (Maple Grove, MN); Jeffrey L. Ardell (Johnson City, TN); Imad Libbus (St. Paul, MN); Badri Amurthur (Los Gatos, CA)
Assignees: LivaNova USA, Inc.; East Tennessee State University
A61N1/36139A61N1/3615A61N1/36053A61N1/36114
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,738,199
App. No.
17/390,481
Granted
Aug 29, 2023
Kind
B2
Abstract

Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A neural fulcrum zone is identified and ongoing neurostimulation therapy is delivered within the neural fulcrum zone. This neural fulcrum zone corresponds to a combination of stimulation parameters at which autonomic engagement is achieved, while the tachycardia-inducing stimulation effects are offset by the bradycardia-inducing effects, thereby minimizing side effects such as significant heart rate changes while providing a therapeutic level of stimulation.

Claims (34)

1. A method of operating an implantable medical device (IMD), the method comprising:

generating a plurality of stimulation signals configured to stimulate a nerve of a patient, each stimulation signal of the plurality of stimulation signals having a duty cycle, a frequency, an amplitude, and a pulse width, wherein generating the plurality of stimulation signals comprises adjusting at least one of the duty cycle, the amplitude, or the pulse width while maintaining a fixed frequency across the plurality of stimulation signals;

detecting a cardiac parameter response of the patient during the generation of the plurality of stimulation signals;

identifying a range of the adjusted at least one of the duty cycle, the pulse width, or the amplitude that results in the cardiac parameter response being between a baseline cardiac parameter and a cardiac parameter decrease threshold; and

delivering a plurality of stimulation signals at a duty cycle, a frequency, an amplitude, and a pulse width resulting in the cardiac parameter response being between the baseline cardiac parameter and the cardiac parameter decrease threshold.

2. The method of claim 1 , wherein the fixed frequency is selected from 2 Hz to 20 Hz.

3. The method of claim 2 , wherein the fixed frequency is 5 Hz.

4. The method of claim 1 , wherein the amplitude is adjusted between at least a subset of 0 mA to 3.5 mA.

5. The method of claim 1 , wherein the amplitude is adjusted while maintaining a fixed pulse width and the fixed frequency.

6. The method of claim 5 , wherein the fixed pulse width is 250 μs.

7. The method of claim 1 , wherein generating the plurality of stimulation signals further comprises generating stimulation signals having the fixed frequency, an amplitude of 1.0 mA, and a pulse width of 250 μs and increasing the at least one of the amplitude or pulse width while maintaining the fixed frequency.

8. The method of claim 7 , wherein the fixed frequency is selected from 2 Hz to 20 Hz.

9. The method of claim 1 , wherein the cardiac parameter response is a heart rate response of the patient.

10. The method of claim 1 , further comprising:

increasing the at least one of the duty cycle, the pulse width, or the amplitude in response to detecting a tachycardia condition, wherein the tachycardia condition is defined by a cardiac parameter increase above the baseline cardiac parameter; and

decreasing the at least one of the duty cycle, the pulse width, or the amplitude in response to detecting a bradycardia condition, wherein the bradycardia condition is defined by a heart rate decrease below the heart rate decrease threshold.

11. An implantable medical device (IMD), comprising:

a neurostimulator configured to deliver a stimulation signal to a nerve of a patient; and

a control system programmed to:

generate a plurality of stimulation signals configured to stimulate a nerve of a patient, each stimulation signal of the plurality of stimulation signals having a duty cycle, a frequency, an amplitude, and a pulse width, wherein generating the plurality of stimulation signals comprises adjusting at least one of the duty cycle, the amplitude, or the pulse width while maintaining a fixed frequency across the plurality of stimulation signals;

detect a cardiac parameter response of the patient during the generation of the plurality of stimulation signals;

identify a range of the adjusted at least one of the duty cycle, the pulse width, or the amplitude that results in the cardiac parameter response being between a baseline cardiac parameter and a cardiac parameter decrease threshold; and

deliver a plurality of stimulation signals at a duty cycle, a frequency, an amplitude, and a pulse width resulting in the cardiac parameter response being between the baseline cardiac parameter and the cardiac parameter decrease threshold.

12. The IMD of claim 11 , wherein the fixed frequency is selected from 2 Hz to 20 Hz.

13. The IMD of claim 12 , wherein the fixed frequency is 5 Hz.

14. The IMD of claim 11 , wherein the amplitude is adjusted between at least a subset of 0 mA to 3.5 mA.

15. The IMD of claim 11 , wherein the control system is configured to adjust the amplitude while maintaining a fixed pulse width and the fixed frequency.

16. The IMD of claim 15 , wherein the fixed pulse width is 250 μs.

17. The IMD of claim 11 , wherein the control system is further configured to generate the plurality of stimulation signals by generating stimulation signals having the fixed frequency, an amplitude of 1.0 mA, and a pulse width of 250 μs and increasing the at least one of the amplitude or pulse width while maintaining the fixed frequency.

18. The IMD of claim 17 , wherein the fixed frequency is selected from 2 Hz to 20 Hz.

19. The IMD of claim 11 , wherein the cardiac parameter response is a heart rate response of the patient.

20. The IMD of claim 11 , wherein the control system is further configured to:

increase the at least one of the duty cycle, the pulse width, or the amplitude in response to detecting a tachycardia condition, wherein the tachycardia condition is defined by a cardiac parameter increase above the baseline cardiac parameter; and

decrease the at least one of the duty cycle, the pulse width, or the amplitude in response to detecting a bradycardia condition, wherein the bradycardia condition is defined by a cardiac parameter decrease below the cardiac parameter decrease threshold.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2023
From: KENKNIGHT, BRUCE H.; LIBBUS, IMAD; AMURTHUR, BADRI
To: CYBERONICS, INC.
Reel/Frame 064244/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2023
From: ARDELL, JEFFREY L.
To: EAST TENNESSEE STATE UNIVERSITY
Reel/Frame 064244/0247 →
CHANGE OF NAME Recorded Jul 13, 2023
From: CYBERONICS, INC.
To: LIVANOVA USA, INC.
Reel/Frame 064272/0380 →
Continuity (5)
Continuation 16422588 · May 24, 2019
Continuation 15600519 · May 19, 2017
Continuation 15230023 · Aug 5, 2016
Continuation 14224922 · Mar 25, 2014
Related Publication 20220016429A1 · Jan 20, 2022